Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REOLYSIN + gemcitabine
- Development stage
- Phase 2
- Lead developer
- Oncolytics Biotech
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**REOLYSIN + gemcitabine** is a combination therapy composed of REOLYSIN (a proprietary formulation of wild-type human reovirus serotype 3, Dearing strain), an oncolytic virus, combined with gemcitabine, a nucleoside analog chemotherapeutic. REOLYSIN selectively infects and lyses cancer cells with activated RAS pathways, leading to immunogenic tumor cell death, apoptosis via endoplasmic reticulum stress, and immune activation. Gemcitabine interferes with DNA synthesis, inhibiting cell proliferation. The combination is being investigated for synergistic antitumor effects, particularly in cancers with high prevalence of RAS pathway mutations such as pancreatic adenocarcinoma. Primary indications studied include advanced and metastatic pancreatic cancer and other refractory solid tumors[1][2][3][4][5].
- Brand names
- Gemzar
- Other names
- oncolytic reovirus + gemcitabine
02
Targets
DNA polymerase familyRNR (Ribonucleotide reductase)MAPK3 (Mitogen-activated protein kinase 1)
Beyond the preview
Go deeper on REOLYSIN + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REOLYSIN + gemcitabine.